Revvity, Inc. (RVTY) 股票分析

公司概述

Revvity, Inc. operates as a provider of comprehensive health sciences solutions, technologies, and services, delivering a broad array of instruments, reagents, software, detection and imaging technologies, as well as extended warranties and training. The company functions within the Healthcare sector, specifically targeting the Diagnostics & Research industry, where it supplies essential assay platforms and software products used for early detection and research applications. As of the latest data, the entity commands a substantial market capitalization of $10.11B and generates annual revenue totaling $2.86B, supported by an operational workforce of 11000 employees. These valuation and revenue figures indicate that Revvity, Inc. holds a significant position within the diagnostic services landscape, reflecting a large-scale operation capable of influencing market dynamics through its extensive product portfolio and service offerings.

财务健康

The company reported revenue of $2.86B, net income of $239.88M, and EBITDA of $840.93M for the trailing twelve months, revealing a substantial gap between top-line revenue and bottom-line profit that highlights a significant cost structure including cost of goods sold, operating expenses, and taxes. This financial profile is underpinned by a robust free cash flow generation of $523.28M, which provides the firm with considerable financial flexibility to fund operations, pursue strategic initiatives, or manage liquidity needs without immediate external financing. Profitability analysis shows a gross margin of 54.8%, an operating margin of 20.1%, and a profit margin of 8.4%, indicating that while the cost of sales is managed efficiently, substantial operating expenses and other non-operating items compress the final net profit relative to revenue. Regarding leverage, the company holds $919.86M in cash against $3.40B in total debt, resulting in a debt-to-equity ratio of 46.87, which suggests a balance sheet that is moderately leveraged given the heavy reliance on debt financing relative to equity. Short-term liquidity is assessed as adequate with a current ratio of 1.68, signifying that the company possesses 1.68 times more current assets than current liabilities to meet obligations due within a year. Efficiency metrics further show a Return on Equity of 3.2% and a Return on Assets of 2.2%, figures that reveal the current management effectiveness in generating returns is relatively low when measured against the invested capital and asset base.

估值评估

Valuation multiples indicate a trailing P/E ratio of 43.88 compared to a forward P/E of 15.07, a significant divergence that implies the market expects earnings to expand dramatically in the coming year to justify the current high multiple. The price-to-book ratio stands at 1.40, suggesting that the stock trades at a 40% premium over its net asset value, reflecting investor confidence in intangible assets like intellectual property or future growth potential rather than tangible book value alone. Alternative valuation metrics provide further context, with a price-to-sales ratio of 3.54 and an EV/EBITDA of 14.97, indicating that the market values the company at a high multiple of its sales and earnings before interest, taxes, depreciation, and amortization. Price momentum analysis shows a 52-week high of $118.30 and a low of $81.36, placing the current trading price within a range that requires calculation relative to these extremes to determine proximity to recent peaks or troughs. Risk assessment utilizes a beta of 1.13, which indicates that the stock's price volatility is approximately 13% higher than that of the broader market, exposing investors to increased sensitivity to general market fluctuations.

Growth & Income

Growth metrics demonstrate a revenue growth rate of 5.9% year-over-year alongside an earnings growth rate of 12.5% year-over-year, indicating that the company's profitability is expanding at a pace significantly faster than its top-line sales growth. Regarding income distribution, the company currently offers a dividend yield of 0.3% with a payout ratio of 13.6%, a conservative payout level that suggests the firm retains the majority of its earnings for reinvestment rather than distributing them to shareholders. The low payout ratio combined with the modest yield confirms that Revvity, Inc. primarily prioritizes retaining earnings to fuel internal growth and operational expansion rather than providing substantial current income to investors. Overall, the company presents a growth-oriented profile characterized by accelerating earnings relative to revenue and a capital allocation strategy focused on reinvestment supported by minimal dividend distributions.